

ASX RELEASE

12 April 2021

## AMPLIA APPOINTS NEW NON-EXECUTIVE DIRECTOR

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX or the Company) is pleased to announce the appointment of Mrs Jane Bell to its Board of Directors.

Dr Warwick Tong, the Chair of Amplia's Board, said: "I am delighted that Mrs Bell has agreed to join our Company's Board and welcome her appointment. As Amplia grows and evolves so should its Board, and Jane will bring an important and complementary skill set to our boardroom. Jane's legal background in banking and finance together with her broad experience in the healthcare sector will contribute a great mix of skills to provide guidance and oversight as we continue to grow the Company."

### **Mrs Jane Bell, BEc, LLB, LLM (Lond), FAICD, Non-Executive Director (commencing 12 April 2021)**

Jane is a banking and finance lawyer and non-executive director with more than 30 years' experience in leading law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Jane has been a non-executive director since 2002, serving on 12 boards including nine health and medical research boards. Jane currently serves as Deputy Chair of Monash Health, Director of Jessie McPherson Private Hospital, Chair of the Community Advisory Group of the Melbourne Genomics Health Alliance and is a Member of the Administrative Appeals Tribunal.

Jane is a former Chair of Melbourne Health (Royal Melbourne Hospital), Chair of Biomedical Research Vic, Deputy Chair of Westernport Water Corporation, Director of UCA Funds Management, WorkSafe Victoria, Hudson Institute of Medical Research-Monash Institute of Medical Research-Prince Henry's Institute of Medical Research, Queensland Institute of Medical Research Trust, Australian Red Cross (Qld) and Victorian Women's Housing Association.

Jane holds a Master of Laws from Kings College, London, Bachelor of Laws from the University of Melbourne, Bachelor of Economics from Monash University and is a Fellow of the Australian Institute of Company Directors.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

### **For Further Information**

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

### **About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Level 21, 90 Collins Street, Melbourne VIC 3000

Email [info@ampliatx.com](mailto:info@ampliatx.com)

[www.ampliatx.com](http://www.ampliatx.com)